Literature DB >> 31051271

Epidemiology of Anaphylaxis in Critically Ill Children in the United States and Canada.

Nicole B Ramsey1, Danielle Guffey2, Katherine Anagnostou3, Nana E Coleman3, Carla M Davis4.   

Abstract

BACKGROUND: Anaphylaxis is a rapid-onset, multisystem, and potentially fatal hypersensitivity reaction with varied reports of prevalence, incidence, and mortality. There are limited cases reported of severe and/or fatal pediatric anaphylaxis.
OBJECTIVE: This study describes the largest cohort of intensive care unit pediatric anaphylaxis admissions with a comprehensive analysis of identified triggers, clinical and demographic information, and probability of death.
METHODS: We describe the epidemiology of pediatric anaphylaxis admissions to North American pediatric intensive care units (PICUs) that were prospectively enrolled in the Virtual Pediatric Systems database from 2010 to 2015. One hundred thirty-one PICUs in North America (United States and Canada) were queried for anaphylaxis International Classification of Diseases, Ninth Revision or International Classification of Diseases, Tenth Revision codes from the Virtual Pediatric Systems database from 2010 to 2015 in the United States and Canada. One thousand nine hundred eighty-nine patients younger than 18 years were identified out of 604,279 total number of patients admitted to a PICU in the database during this time frame.
RESULTS: The primary outcome was mortality, which was compared with patient and admission data using Fisher exact test. Secondary outcomes (intubation, length of stay, mortality risk scores, systolic blood pressure, and pupillary reflex) were analyzed using the Kruskal-Wallis test or Wilcoxon rank-sum test, as appropriate. One thousand nine hundred eighty-nine patients with an anaphylaxis International Classification of Diseases code were identified in the database. One percent of patients died because of critical anaphylaxis. Identified triggers for fatal cases were peanuts, milk, and blood products. Peanuts were the most common trigger. Children were mostly male when younger than 13 years, and mostly female when 13 years and older. Average length of stay was 2 days. There was a higher proportion of Asian patients younger than 2 years or when the trigger was food.
CONCLUSIONS: This is the largest study to describe pediatric critical anaphylaxis cases in North America and identifies food as the most common trigger. Death occurs in 1% of cases, with intubation occurring most commonly in the first hour. The risk for intensive care unit admission in children underscores the serious nature of anaphylaxis in this population.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adolescent; Anaphylaxis; Critically ill; ICU; Milk; Mortality; Peanut; Pediatric

Mesh:

Substances:

Year:  2019        PMID: 31051271     DOI: 10.1016/j.jaip.2019.04.025

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  11 in total

1.  Allergy and immunology in young children of Japan: The JECS cohort.

Authors:  Kiwako Yamamoto-Hanada; Kyongsun Pak; Mayako Saito-Abe; Limin Yang; Miori Sato; Makoto Irahara; Hidetoshi Mezawa; Hatoko Sasaki; Minaho Nishizato; Kazue Ishitsuka; Yukihiro Ohya
Journal:  World Allergy Organ J       Date:  2020-11-07       Impact factor: 4.084

2.  Provider recommendations and maternal practices when providing breast milk to children with immunoglobulin E-mediated food allergy.

Authors:  Hannah Wangberg; Samantha R Spierling Bagsic; John Kelso; Kathleen Luskin; Cathleen Collins
Journal:  Ann Allergy Asthma Immunol       Date:  2021-02-24       Impact factor: 6.347

3.  Factors Associated with Frequency of Peanut Consumption in Korea: A National Population-Based Study.

Authors:  Minyoung Jung; Jayun Kim; Su Mi Ahn
Journal:  Nutrients       Date:  2020-04-25       Impact factor: 5.717

4.  Food anaphylaxis in the United Kingdom: analysis of national data, 1998-2018.

Authors:  Alessia Baseggio Conrado; Despo Ierodiakonou; M Hazel Gowland; Robert J Boyle; Paul J Turner
Journal:  BMJ       Date:  2021-02-17

Review 5.  Management of Anaphylaxis During the SARS-CoV-2 Pandemic.

Authors:  Kanwaljit K Brar; Albana Harizaj; Anna Nowak-Wegrzyn
Journal:  Curr Treat Options Allergy       Date:  2021-03-10

Review 6.  Incidence of anaphylaxis and accidental peanut exposure: A systematic review.

Authors:  Antonella Muraro; J Wesley Sublett; Tmirah Haselkorn; Caroline Nilsson; Thomas B Casale
Journal:  Clin Transl Allergy       Date:  2021-10       Impact factor: 5.871

7.  Allergy to Peanuts imPacting Emotions And Life (APPEAL): The impact of peanut allergy on children, teenagers, adults and caregivers in the UK and Ireland.

Authors:  Marina Tsoumani; Lynne Regent; Amena Warner; Katy Gallop; Ram Patel; Robert Ryan; Andrea Vereda; Sarah Acaster; Audrey DunnGalvin; Aideen Byrne
Journal:  PLoS One       Date:  2022-02-07       Impact factor: 3.240

8.  Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.

Authors:  Montserrat Fernandez-Rivas; Andrea Vereda; Brian P Vickery; Vibha Sharma; Caroline Nilsson; Antonella Muraro; Jonathan O'B Hourihane; Audrey DunnGalvin; George du Toit; Katharina Blumchen; Kirsten Beyer; Alex Smith; Robert Ryan; Daniel C Adelman; Stacie M Jones
Journal:  Allergy       Date:  2021-09-24       Impact factor: 14.710

9.  APPEAL-2: A pan-European qualitative study to explore the burden of peanut-allergic children, teenagers and their caregivers.

Authors:  Audrey DunnGalvin; Katy Gallop; Sarah Acaster; Frans Timmermans; Lynne Regent; Sabine Schnadt; Marcia Podestà; Angel Sánchez; Robert Ryan; Pascale Couratier; Mary Feeney; Betina Hjorth; Helen R Fisher; Katharina Blumchen; Andrea Vereda; Montserrat Fernández-Rivas
Journal:  Clin Exp Allergy       Date:  2020-09-15       Impact factor: 5.018

10.  Global patterns in anaphylaxis due to specific foods: A systematic review.

Authors:  Alessia Baseggio Conrado; Nandinee Patel; Paul J Turner
Journal:  J Allergy Clin Immunol       Date:  2021-05-01       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.